Details of the Drug Combinations

General Information of This Drug (ID: DM9LFYN)

Drug Name

Tesetaxel DM9LFYN

Synonyms

Tesetaxel; DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[1]
Bladder cancer	2C94	Phase 2	[2]
Gastric adenocarcinoma	2B72	Phase 2	[2]
Melanoma	2C30	Phase 2	[2]
Prostate cancer	2C82.0	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rifampicin + Tesetaxel	DCG7PMD	Rifampicin	Advanced Solid Tumors	[3]
Tesetaxel + Capecitabine	DCU1RP0	Capecitabine	Gastric Carcinoma	[4]
Tesetaxel + Itraconazole	DCME3T7	Itraconazole	Advanced Solid Tumors	[3]
Tesetaxel + Capecitabine	DCEWC7E	Capecitabine	Breast Cancer	[5]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT04312282) The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
4	ClinicalTrials.gov (NCT01573468) Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
5	ClinicalTrials.gov (NCT03858972) Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC